Changes in Th9 and Th17 Lymphocytes and Functional Cytokines and their Relationship with Thyroid-Stimulating Hormone Receptor Antibodies at Different Stages of Graves' Disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200060772

Enrollment

Unknown

Registered

2022-06-11

Start date

2021-04-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' disease

Interventions

control group:NA

newly diagnosed GD:NA

TRAb+ in remission:NA

TRAb- in remission:NA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.

Exclusion criteria

Exclusion criteria: Patients with acute or chronic infections, other autoimmune or chronic diseases, malignant tumors, liver and kidney insufficiency, pregnancy, breastfeeding, or those taking interferon, glucocorticoids, antibiotics, lithium carbonate, or other drugs that affect the immune system and thyroid function.

Design outcomes

Primary

Measure	Time frame
thyroid function;Th17 Cell Frequencies;Th9 Cell Frequencies;IL-9;IL-17;mRNA Expression;	—

Countries

China

Contacts

Public ContactHui Chen

Lanzhou University Second Hospital

renx17@lzu.edu.cn+86 18189532979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026